Doxorubicin Containing Nanoplexes and Uses Thereof

2:

• The tumor-targeting nanoplex of claim 1, further comprising a second tumor-targeting agent conjugated to the tumor targeting nanoplex to enhance targeting thereof.

3:

• The tumor-targeting nanoplex of claim 3, wherein the second tumor-targeting agent is cRGD-PEG-H3K4b, RGD-PEG-H3K4b, NGR-PEG-H3K4b, or CGKRK-PEG-H3K4b.

4:

• The tumor-targeting nanoplex of claim 1, wherein the first tumor-targeting agent is a linear histidine-lysine peptide sequence or a branched histidine-lysine peptide each comprising at least one —KHHK— peptide sequence.

5:

• The tumor-targeting nanoplex of claim 1, wherein the tumor-targeting agent is a delivery agent.

6:

• The tumor-targeting nanoplex of claim 1, wherein the chemotherapeutic agent is doxorubicin, epirubicin, daunorubicin, or mitoxantrone.

7:

• The tumor-targeting nanoplex of claim 1, wherein the chemotherapeutic agent and the plasmid DNA are in a wt/wt ratio of 1:2, 1:4, 1:8, 1:16, or 1:32.

8:

• The tumor-targeting nanoplex of claim 7, wherein the chemotherapeutic agent and the plasmid DNA are in a ratio of 1:8 wt/wt.

9:

• The tumor-targeting nanoplex of claim 7, wherein the chemotherapeutic agent and the plasmid DNA are in a ratio of 1:16 wt/wt.

10:

• The tumor-targeting nanoplex of claim 1, wherein the first tumor targeting agent and the plasmid DNA are in a wt/wt ratio of 1:2, 1:4, 1:6, or 1:8.

11:

• The tumor-targeting nanoplex of claim 10, wherein the first tumor targeting agent and the plasmid DNA are in a ratio of 1:2 wt/wt.

12:

• The tumor-targeting nanoplex of claim 1, wherein the nanoplex has a size of about 50 nm to about 250 nm.

13:

• A method for treating a cancer in a subject, comprising administering to the subject a nanoplex comprising a chemotherapeutic agent DNA conjugate comprising a chemotherapeutic agent intercalated with a plasmid DNA and a first tumor-targeting agent ionically linked to the chemotherapeutic agent DNA conjugate.

14:

• The method of claim 13, wherein the nanoplex further comprises a second tumor-targeting agent conjugated to the tumor-targeting nanoplex to enhance targeting thereof.

15:

• The method of claim 14, wherein the second tumor-targeting agent is cRGD-PEG-H3K4b, RGD-PEG-H3K4b, NGR-PEG-H3K4b, or CGKRK-PEG-H3K4b.

16:

• The method of claim 13, wherein the first tumor-targeting agent is a linear histidine-lysine peptide or a branched histidine-lysine peptide with at least one KHHK peptide sequence.

17:

• The method of claim 13, wherein the first tumor-targeting agent is a delivery agent.

18:

• The method of claim 13, wherein the cancer is a breast cancer, an ovarian cancer, a melanoma, a colon cancer, a pancreatic cancer, a brain cancer, a bladder cancer, a lung cancer, or a prostate cancer.

19:

• The method of claim 13, wherein the chemotherapeutic agent is doxorubicin, epirubicin, daunorubicin or mitoxantrone.

20:

• The method of claim 13, wherein the chemotherapeutic agent is administered in a therapeutically effective amount of about 0.016 mg/Kg to about 0.2 mg/Kg.

21:

• The method of claim 13, wherein the first tumor-targeting agent and the plasmid DNA are in a wt/wt ratio of 1:2, 1:4, 1:6, or 1:8.

22:

• The method of claim 21, wherein the first tumor-targeting agent and the plasmid DNA are in a ratio of 1:2 wt/wt.

23:

• The method of claim 13, wherein the chemotherapeutic agent and the plasmid DNA are in a wt/wt ratio of 1:2, 1:4, 1:8, 1:16, or 1:32.

24:

• The method of claim 23, wherein the chemotherapeutic agent and plasmid DNA are in a ratio of 1:8 wt/wt.

25:

• The method of claim 23, wherein the chemotherapeutic agent and the plasmid DNA are in a ratio of 1:16 wt/wt.

26:

• The method of claim 1, wherein the nanoplex has a size of about 50 nm to about 250 nm.

27-45. (canceled)